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Abstract Background Time in therapeutic range (TTR) measures the quality of vitamin K
antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized
SAMe-TT2-R2 score (2 vs. < 2 points) can predict if adequate TTR is unlikely to be
achieved.
Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism
(VTE) randomized to the warfarin arm of the Hokusai-VTE trial.
Patients and Methods A total of 3,874 patients were included in the primary analysis
(day 31–180 from randomization). The efficacy and safety outcomes were sympto-
matic recurrent VTE and major or clinically relevant non-major bleeding.
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Introduction
Direct oral anticoagulants (DOACs) represent the drugs of
choice formost patients diagnosedwith acute venous throm-
boembolism (VTE) based on the results of large phase III
trials, which compared them to conventional international
normalized ratio (INR)-adjusted vitamin K antagonist (VKA)
anticoagulation.1 One of the factors contributing to the
favourable efficacy and safety of DOACs is their more stable
pharmacokinetic profile, which provides steady therapeutic
levels following the administration of a fixed-dose regimen.
Despite this, a proportion of patients with acute VTE are
still candidates for VKA, especially those with absolute or
relative contraindications to DOAC use or taking potentially
interacting co-medications.2–5 National restrictions for drug
reimbursement, and patients’ or physicians’ preferences also
influence the choice of anticoagulant therapy for the man-
agement of acute VTE. Since the risk of recurrence and
bleeding during VKA therapy greatly depends on the quality
of anticoagulation, as estimated by the individual time in
therapeutic INR range (TTR),6–8 predicting whether a patient
is likely to achieve a good TTR is crucial to select the right
therapy for the right patient.
The SAMe-TT2-R2 score (►Table 1) was developed to
identify patients with atrial fibrillation who would perform
well (or not) on VKA and aid therapeutic decision mak-
ing.9–11 A position document released by the European
Society of Cardiology Working Group on Thrombosis sug-
gested that, in patients with atrial fibrillation and a SAMe-
TT2-R2 score predicting poor TTR, DOACs might represent a
better option for initial treatment.12 Only a few adequately
sized studies validated the score in VTE patients and inves-
tigated correlations with clinical outcomes.13–15 It remains
unclear whether the SAMe-TT2-R2 score may influence the
choice of anticoagulant therapy after VTE.
Our objectives were to identify independent predictors of
individual TTR in the warfarin arm of the Hokusai-VTE trial,
which compared the direct oral anti-Xa inhibitor edoxaban
versus standard VKA therapy for the treatment of acute VTE,
and provide a temporal, geographical and independent
external validation of the SAMe-TT2-R2 score in this setting.
Patients and Methods
Study Design of the Hokusai-VTE
The Hokusai-VTE was a double-blind, double-dummy, pla-
cebo-controlled phase III trial that randomized patients diag-
nosed with acute symptomatic VTE to either edoxaban or
warfarinafteran initial courseofheparin. Thestudydesignand
results have been previously reported (ClinicalTrials.gov iden-
tifier: NCT00986154).16,17 In brief, patients enrolled in the
Hokusai-VTE trial were adults with an episode of objectively
confirmedacute, symptomatic proximal deepvein thrombosis
(DVT) and/or pulmonary embolism (PE). Main exclusion cri-
teria included severe renal dysfunction (creatinine clearance
< 30mL/min), active cancer, use of chronic dual anti-platelets,
Results The rates of recurrent VTE andbleeding eventswerehigher in patientswith a TTR
below themedian (< 66% vs.66%) resulting in an absolute risk difference (ARD) ofþ0.5%
(95% confidence interval: 0%,þ1.1%) andþ2.2% (0.9%,þ3.5%), respectively. Patients with
highSAMe-TT2-R2 scorewere76%of total andhad lowermedianTTR (64.7%vs.70.7%). The
SAMe-TT2-R2 score exhibited low negative (0.59) and positive (0.52) predictive value (TTR
threshold 66%), and poor discrimination (c-statistic, 0.58). ARDbetween patients with high
and low score was 0% (–0.6%, þ0.7%) for recurrence and þ1.3% (–0.1%, þ2.7%) for
bleeding. Results were confirmed in sensitivity analyses focusing on thewhole study period
(day 1–365).
Conclusion In VTE patients, the SAMe-TT2-R2 score showed unsatisfactory discrimi-
nation and predictive value for individual TTR and did not correlate well with clinical
outcomes. The choice of starting a patient on VKA cannot be based on this parameter
and its routine use after VTE may not translate into clinical usefulness.
Table 1 The SAMe-TT2-R2 score
Item Points
Female sex 1
Age < 60 years 1
Medical history of > 2 co-morbidities
(e.g. hypertension, diabetes, coronary
artery disease/myocardial infarction,
peripheral arterial disease, congestive
heart failure, prior stroke, pulmonary
disease, hepatic or renal disease)
1
Concomitant medications (interacting
drugs, e.g. amiodarone for rhythm
control)a
1
Tobacco use (within 2 y)a 2
Non-Caucasian origins 2
SAMe-TT2-R2 classes Total points
Low probability of not doing well on
VKA – Higher TTR expected
0–1
High probability of not doing well on
VKA – Lower TTR expected
2 or more
Abbreviations: TTR, time in therapeutic range; VKA, vitamin K antagonist.
aFor the present study, separate analyses have been performed for (1) all
potential interacting drugs, and (2) amiodarone only. Moreover, we
only considered ‘current tobacco use’ at the time of enrolment.
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aspirin (> 100 mg/day) and use of non-steroidal anti-inflam-
matory drugs or potent P-glycoprotein inhibitors. The Hoku-
sai-VTE protocol had been reviewed by the institutional
review board at each participating site and all patients pro-
vided written informed consent.
Study Treatment
All patients received open-label unfractionated heparin or
low-molecular weight heparin for at least 5 consecutive days.
Edoxaban or warfarin was given for at least 3 and up to
12 months after enrolment. The length of anticoagulation
was individualized and the decision left at the discretion of
the treating physicians. Edoxaban was given at a standard
dose of 60 mg once daily; the dose was reduced to 30 mg
once daily in patients with a creatinine clearance of 30 to 50
mL/min, body weight of 60 kg or taking concomitant P-
glycoprotein inhibitors. The warfarin dose was adjusted to
maintain an INR comprised between 2.0 and 3.0, as mea-
sured locally by point-of-care devices.16,17
Time in Therapeutic Range
We calculated individual TTR in thewarfarin armof Hokusai-
VTE for the period elapsing between day 31 and 180 after
enrolment, inclusively. We have chosen this timeframe since
day 30 represents the time by which ‘stable’ therapeutic
individualized dosing is achieved after the early inception
phase of VKA treatment and acute factors (including INR
management during hospitalization) are less likely to play a
role.18 The timeframe for censoring (day 180) has been
previously used in similar studies on TTR, phase III trials18,19
and risk assessment model validations.20,21
We additionally performed non-predefined sensitivity
analysis focusing on the whole study period (day 1–365)
on anticoagulant, provided that initial (day 1–30) TTRmay be
difficult to predict due to the concomitance of transient
influencing factors (e.g. hospitalization, acute infection, co-
medications) and, vice versa, that extended VKA anticoagu-
lationmay have been preferred in patients who had achieved
adequate TTR during the first 6 months of therapy.
We used the method of linear interpolated INR to calcu-
late individual TTR in patients with INR measurement gaps
no longer than 42 days.22 The compliance to the study drug
was calculated based on the compliance to placebo edoxaban
of patients randomized to the warfarin arm of the study,
according with the formula ‘number of tablets taken by
number of tablets due’.
The SAMe-TT2-R2 Score
The SAMe-TT2-R2 score was derived for each patient by
adding one point for any of the following items9: (1) female
sex, (2) age < 60 years, (3) at least two of the following:
hypertension, diabetes, coronary artery disease/myocardial
infarction, peripheral arterial disease, congestive heart fail-
ure, previous stroke, pulmonary disease (i.e. chronic obstruc-
tive pulmonary disease), hepatic or renal disease, (4)
treatment with interacting drugs (mainly amiodarone),
and two points for the following: (5) tobacco use (within 2
years) and (6) non-Caucasian origins (►Table 1).
The main discrepancy between our analysis and the
original SAMe-TT2-R2 score was represented by the item
‘tobacco use (within 2 years)’. This variable was not available
in the Hokusai-VTE case report form and, therefore, we used
‘current tobacco use’ for the classification of patients.
Furthermore, the score was derived in the atrial fibrillation
setting, where amiodarone represented the principal inter-
fering co-medication known to exert an effect on INR levels.
Since the proportion of VTE patients taking amiodarone is
usually extremely low,10 and atrial fibrillation was an exclu-
sion criteria in Hokusai-VTE,17 we calculated the SAMe-TT2-
R2 score accounting for the use of (1) major interfering drugs
based on the Food and Drug Administration prescribing
information (a full list is provided in the ►Supplementary
Material, available in the online version) and (2) amiodarone
only.
The primary evaluation of the score was based on dichot-
omized classes, namely, low (0–1 point) versus high (2 points
or more) SAMe-TT2-R2 scorewith a high SAMe-TT2-R2 score
predicting poor TTR. We performed separate evaluation of
the trichotomized score (0–1 point, 2 points, 3 points or
more), as previously reported.15,23,24
Clinical Outcomes
In Hokusai-VTE, all patients, regardless of treatment dura-
tion, were followed for 12 months or until the end-of-study
date. For the present analysis, we considered events occur-
ring during anticoagulant treatment between day 31 and 180
from randomization.
The primary efficacy outcomewas symptomatic recurrent
VTE (defined as DVT and/or fatal, or non-fatal, PE). The
principal safety outcome was clinically relevant bleeding
(the composite of major and clinically relevant non-major
bleeding). Major bleeding was defined as overt bleeding that
was associated with a reduction in haemoglobin of 2 g/dL
or requiring transfusion of two or more units of blood,
occurred at a critical site or contributing to death. Clinically
relevant non-major bleeding was defined as overt bleeding
that did notmeet the criteria formajor bleeding but required
medical intervention, unscheduled contact with a clinician,
interruption of study drug or discomfort or impairment of
daily activities.17 In addition, we focused on a composite
outcome including recurrent VTE or clinically relevant bleed-
ing. All suspected outcomes have been adjudicated by an
independent committee.16,17
Statistical Analysis
We used counts and percentages for describing categorical
data and mean/median (standard deviation [SD]/interquar-
tile range [IQR]) for continuous variables, where appropriate.
Comparisons between groups were performed using the
two-sided Wilcoxon non-parametric test for non-normally
distributed data. We used linear mixed regression for our
unadjusted and adjusted models to evaluate the impact of
independent baseline factors on TTR (dependent variable).
The variables were selected on the basis of clinical relevance,
frequency of missing values and available literature on this
topic: their detailed description has already been provided
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elsewhere.17 The unstandardized regression coefficient for
the predictor represents the difference in response in terms
of TTR change when baseline factor status changes. The
diagnostic quality of the multi-level SAMe-TT2-R2 was eval-
uated using receiver operator characteristic curve analysis
(95% confidence interval [95% CI]) as a measure of discrimi-
nation. For the dichotomized SAMe-TT2-R2 score, we calcu-
lated odds ratio (OR), sensitivity, specificity, negative
predictive value (NPV) and positive predictive value (PPV)
accompanied by 95% CI for the outcome of low TTR. Low TTR
was primarily defined by using themedian value of the study
population (66%) as a threshold.
We calculated event rates by dividing the number of
patients with an event for the total number of subjects
included in the safety population between day 31 and 180.
To explore the time distribution of the events, we calculated
the monthly rate for each outcome, which provides better
visual overview compared with the Kaplan–Meier curve
estimator. Finally, we performed univariate Cox regression
model analysis to calculate the hazard ratios (HRs; 95% CI) of
TTR levels or SAMe-TT2-R2 score classes for the occurrence of
thromboembolic and bleeding complications (dependent
variables). The difference between groups are also provided
as absolute risk reduction (ARD; 95% CI).
Results
A total of 8,292 patients were enrolled in the Hokusai-VTE
between 2010 and 2012, of whom 4,122 were randomized
to receive warfarin. Median duration of treatment with
the study drug was 266 days: 528 (12.8%) patients were
treated for 3 months or less, 1,084 (26.3%) for 3 to 6 months
and 2,510 (60.9%) for 6 months or longer. Of these, 3,903
completed at least 30 days of anticoagulant treatment and
3,874, who had at least one INRmeasurement available after
day 30, were included in the present analysis. The baseline
characteristics of the study population are depicted
in ►Table 2.
Between day 31 and 180, median individual TTR (range:
2.0–3.0) was 66.0% (IQR: 50.4–80.6%). Mean TTR was 63.7%
(SD, 22.4%) with 21.5% (SD, 20.8%) of time spent below and
14.8% (SD, 16.5%) above the therapeutic range (INR: 2.0–3.0).
We summarized the drug compliance to placebo edoxaban of
patients randomized to the warfarin arm and geographical
variations of TTR in ►Supplementary Tables S1 and S2
(available in the online version).
Factors Influencing the Time in Therapeutic Range
After adjustment for clinically relevant baseline characteristics
reported in ►Table 2, we observed that patients of Afro-
American or Asian origins had lower individual TTR (–5.2 and
–7.1%, respectively)with95%CI not including zero. Tobaccouse
(–3.9%), the presence of anaemia at baseline (–4.9%) and the
presence of at least one of the following criteria (a creatinine
clearance of 30–50 mL/min, body weight < 60 kg or P-glyco-
protein inhibitor administration: –2.9%) were also associated
with lower TTR. Vice versa, patients taking statin (þ2.7%),
consuming alcohol (þ1.8%) and with PE as the presenting
location of acute VTE (þ2.6%) had higher TTR.
►Supplementary Table S3 (available in the online version)
depicts the coefficients resulting from the univariate analysis.
Time in Therapeutic Range and Clinical Endpoints
Recurrent VTE occurred in 1.0% of patients with an indivi-
dual TTR of < 66% and in 0.5% of patients with TTR 66%
(HR: 2.02; 95% CI: 0.94–4.38), corresponding to an ARD of
0.5% (95% CI: 0.0%, 1.1%). Clinically relevant bleeding
occurred in 5.5% (TTR < 66%) and 3.3% (TTR 66%) of
patients within the two groups, respectively, for HR of
1.75 (95% CI: 1.28–2.38) and ARD of 2.2% (95% CI: 0.9%,
3.5%; ►Table 3). The composite outcome occurred in 6.4% of
patients with low and 3.8% with high TTR (HR: 1.76; 95% CI:
1.32–2.35 and ARD 2.7%; 95% CI: 1.3–4.1%). The time
distribution of the events appeared to be left skewed
with more (especially bleeding) events recorded between
day 31 and 90 in patients with low TTR, as depicted
in ►Supplementary Fig. S1 (available in the online version).
External Validation of the SAMe-TT2-R2 Score for the
Prediction of TTR Levels
By applying the conventional score threshold (0–1 vs. 2
points or more), 943 (24%) patients were classified in the
low and 2,931 (76%) in the high SAMe-TT2-R2 class by
considering the use of any potentially interfering co-medica-
tions, which was reported in 47% of patients (►Table 4).
MedianTTRwas 70.7% (IQR: 56.5–84.0%) in patientswith low
and 64.7% (IQR: 48.7–79.1%) with high score (Wilcoxon two-
sided test, p < 0.0001). The time above INR 3.0 was 10.7% in
patients with low and 9.5% in patients with high score. The
time below INR 2.0 was 12.4 and 18.1% in the two groups,
respectively.
High SAMe-TT2-R2 score predicted low TTR with OR of
1.55 (95% CI: 1.34–1.80) for TTR < 66% (vs. TTR66%) andOR
of 1.86 (95% CI: 1.54–2.26) for TTR < 50% (vs. TTR 50%). c-
Statistics of the continuous SAMe-TT2-R2 score were 0.58
(95% CI: 0.56–0.60) and 0.59 (95% CI: 0.57–0.61) for these
two TTR thresholds, respectively. NPV increased from 0.59
(95% CI: 0.56–0.62) for the 66% threshold to 0.84 (95% CI:
0.81–0.86) for the 50% threshold.
We also calculated the score by excluding the item ‘treat-
ment with interacting drugs’, since none of the patients used
amiodarone. In this analysis, 1,400 (36%) patients were
classified in the low and 2,474 (64%) in the high SAMe-
TT2-R2 class. The performance of the score was similar as
considering all potential interfering drugs (►Supplementary
Tables S4 and S5, available in the online version).
SAMe-TT2-R2 Score and Clinical Endpoints
In patients with a SAMe-TT2-R2 score calculated accounting
for multiple potential interfering drugs, the rate of recurrent
VTE was 0.8% in the high (SAMe-TT2-R2 2 points) versus
0.7% in the low (SAMe-TT2-R2 < 2 points) risk group for HR
of 1.02 (95% CI: 0.42–2.49) and ARD of 0% (95% CI: –0.6%,
0.7%). The rates of clinically relevant bleeding were 4.7%
versus 3.4% (HR: 1.34 [95% CI: 0.91–1.97] and ARD: þ1.3%
[95% CI: –0.1%,þ2.7%]), respectively. The composite outcome
Thrombosis and Haemostasis
Quality of Warfarin Control in Hokusai-VTE Barco et al.
D
ow
nl
oa
de
d 
by
: J
on
at
ha
n 
Do
ux
fils
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
Table 2 Baseline characteristics of the study population
Variable Valuea Adjusted effect on TTR,
% (95% CI) – Day 31–180
Adjusted effect on TTR,
% (95% CI) – Day 1–365
Age, I quartile (18–44 y) 1,026/3,874 (26.5) Reference Reference
Age, II quartile (45–56 y) 930/3,874 (24.0) –0.2 (–2.2; þ1.9) –0.7 (–2.5; þ1.0)
Age, III quartile (57–68 y) 1,002/3,874 (25.9) þ1.9 (–0.3; þ4.1) þ1.1 (–0.8; þ3.0)
Age, IV quartile (69–95 y) 916/3,874 (23.6) þ0.8 (–1.9; þ3.5) –0.4 (–2.8; þ1.9)
Female sex, n (%) 1,644/3,874 (42.4) –0.7 (–2.2; þ0.9) –0.2 (–1.5; þ1.2)
Ethnicity
White 2,730/3,874 (70.5) Reference Reference
Afro-American 128/3,874 (3.3) –5.2 (–9.8; –0.7) –6.4 (–10.3; –2.4)
Asian 802/3,874 (20.7) –7.1 (–9.6; –4.6) –6.0 (–8.2; –3.8)
Other 214/3,874 (5.5) þ1.3 (–2.6; þ5.2) þ0.7 (–2.8; þ4.2)
Body mass index
BMI < 18.5 67/3,831 (1.7) Reference Reference
BMI 18.5–24.9 1,071/3,831 (28.0) –1.6 (–7.1; þ3.9) –1.9 (–6.7; þ2.8)
BMI 25.0–30.0 1,485/3,831 (38.8) –0.5 (–6.2; þ5.2) –0.7 (–5.6; þ4.1)
BMI > 30.0 1,208/3,831 (31.5) –0.4 (–6.2; þ5.5) –0.8 (–5.7; þ4.2)
Creatinine clearance
CrCL < 50 mL/min 194/3,669 (5.3) Reference Reference
CrCL 50–80 mL/min 832/3,669 (22.7) –0.7 (–4.3; þ2.9) þ1.1 (–2.0; þ4.2)
CrCL >80 mL/min 2,643/3,669 (72.0) –0.7 (–4.6; þ3.2) þ1.4 (–1.9; þ4.7)
Presenting location of acute
venous thromboembolism
Pulmonary embolism
(with or without deep vein thrombosis)
1,548/3,874 (40.0) þ2.6 (þ0.9; þ4.2) þ1.4 (–0.04; þ2.8)
Provoked event 1,324/3,874 (34.2) þ0.9 (–0.7; þ2.5) 0.0 (–1.3; þ1.4)
Previous venous thromboembolism 704/3,874 (18.2) þ0.5 (–1.4; þ2.3) þ1.2 (–0.4; þ2.8)
Active cancer 83/3,874 (2.1) –3.4 (–8.4; þ1.6) –2.9 (–7.1; þ1.2)
History of diabetes 396/3,874 (10.2) –0.8 (–3.3; þ1.6) –0.6 (-2.7; þ1.4)
History of chronic heart failure 84/3,874 (2.2) –3.5 (–8.4; þ1.5) –4.2 (–8.4; þ0.1)
History of pulmonary disease 628/3,874 (16.2) –0.6 (–2.7; þ1.4) –0.9 (-2.7; þ0.8)
Anaemia 947/3,874 (24.4) –4.9 (–6.6; –3.2) –3.7 (–5.1; –2.2)
History of hypertension 1,547/3,874 (39.9) þ0.6 (1.2; þ2.3) þ0.7 (–0.8; þ2.2)
Number of co-medications
0–2 1,122/3,874 (28.9) Reference Reference
3–5 1,286/3,874 (33.2) –0.5 (–2.5; þ1.4) –0.5 (–2.2; þ1.1)
> 5 1,466/3,874 (37.8) –0.8 (–3.1; þ1.4) –0.8 (–2.7; þ1.2)
Anti-platelet use 1,194/3,874 (30.8) –0.5 (–2.2; þ1.2) 0 (–1.5; þ1.5)
Statin use 484/3,874 (12.5) þ2.7 (þ0.3; þ5.0) þ3.0 (þ1.0; þ5.0)
Alcohol use (any amount) 1,314/3,874 (33.9) þ1.8 (þ0.1; þ3.5) þ0.5 (–0.9; þ2.0)
Tobacco use 758/3,874 (19.6) –3.9 (–5.8; –2.1) –3.9 (–5.5; –2.3)
CrCl 30–50 mL/min, a body weight 60 kg
or use of potent P-glycoprotein inhibitors
655/3,874 (16.9) –2.9 (–5.3; –0.5) –2.6 (–4.7; –0.5)
Abbreviations: BMI, body mass index; CI, confidence interval; CrCL, creatinine clearance; TTR, time in therapeutic range.
aFrequencies refer to subjects satisfying the criteria for inclusion in the primary analysis (N ¼ 3,874; day 31–180).
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occurred in 5.4 and 4.0% of patients (HR: 1.31; 95% CI: 0.91–
1.87 and ARD: 1.4%; 95% CI: –0.3%; 2.8%), respectively
(►Table 3). No relevant differenceswere observed by exclud-
ing the item ‘treatment with interacting drugs’
(►Supplementary Table S5, available in the online version).
When we considered the trichotomized score (0–1 vs. 2
vs. 3 points or more), patients with 3 points or more had a
rate of recurrent VTE of 0.9% (HR: 1.16 for 3 vs. 0–1 points
[95% CI: 0.46–2.94] and ARD: þ0.2% [95% CI: –0.5%, þ3.3%]).
The rate of clinically relevant bleeding was 5.2% (HR: 1.49 for
3 vs. 0–1 points [95% CI: 1.00–2.23] and ARD: þ1.8% [95% CI:
þ0.3, þ3.3]), respectively (►Table 3 and ►Supplementary
Table S5, available in the online version).
Sensitivity Analysis for the Whole Study
Period (Day 1–365)
In 3,984 patients with available INR measurements followed
during the whole study period, the adjusted linear regression
analysis didnot lead to the identificationof additional baseline
factors associated with significant changes in TTR (►Table 2).
We confirmed the association between low (< 66% vs. 66%)
TTR and recurrent VTE (HR: 1.91; 95% CI: 1.12–3.25), clinical
relevant bleeding (HR: 1.51; 95% CI: 1.23–1.86) and the
composite outcome (HR: 1.54; 95% CI: 1.27–1.86).
Consistently with the primary analysis focusing on the
period elapsing between day 31 and 180, the SAMe-TT2-R2
score showed poor discrimination (c-statistic: 0.58, irrespec-
tive of whether we accounted or not for all potentially
interfering co-medications) and low predictive values for
individual TTR (data not shown). High (2 points or 3
points vs. < 2 points) SAMe-TT2-R2 score was associated
with clinically relevant bleeding, but showed a tendency for
inverse association with recurrent VTE (►Supplementary
Table S6, available in the online version).
Discussion
The TTR is an indirect, but arguably the best available,
measure of the quality of VKA treatment and correlates
well with the individual thrombotic and bleeding risk during
Table 3 Clinical endpoints in patients stratified by TTR and classes of the SAMe-TT2-R2 score
Group n/N (%) Crude hazard ratio
(95% CI)
Absolute risk difference,
Δ% (95% CI)
Time in therapeutic range (TTR)
Recurrent VTE TTR < 66% 20/1,914 (1.0) 2.02 (0.94–4.38) 0.5 (0.0, 1.1)
TTR  66% 10/1,960 (0.5) Reference Reference
Clinically relevant bleeding TTR < 66% 105/1,914 (5.5) 1.75 (1.28–2.38) 2.2 (0.9, 3.5)
TTR  66% 64/1,960 (3.3) Reference Reference
Recurrent VTE or clinically
relevant bleeding
TTR < 66% 123/1,914 (6.4) 1.76 (1.32–2.35) 2.7 (1.3; 4.1)
TTR  66% 74/1,960 (3.8) Reference Reference
Dichotomized SAMe-TT2-R2 score
Recurrent VTE 2 points 23/2,931 (0.8) 1.02 (0.42–2.49) 0.0 (–0.6, 0.7)
0–1 points 7/943 (0.7) Reference Reference
Clinically relevant bleeding 2 points 137/2,931 (4.7) 1.34 (0.91–1.97) 1.3 (–0.1, 2.7)
0–1 points 32/943 (3.4) Reference Reference
Recurrent VTE or clinically
relevant bleeding
2 points 159/2,931 (5.4) 1.31 (0.91–1.87) 1.4 (–0.3; 2.8)
0–1 points 38/943 (4.0) Reference Reference
Three-class SAMe-TT2-R2 score
Recurrent VTE 3 points 18/2,010 (0.9) 1.16 (0.46–2.94) 0.2 (–0.5, 0.8)
2 points 5/921 (0.5) 0.72 (0.22–2.32) –0.2 (–0.9, 0.5)
0–1 points 7/943 (0.7) Reference Reference
Clinically relevant bleeding 3 points 104/2,010 (5.2) 1.49 (1.00–2.23) 1.8 (0.3, 3.3)
2 points 33/921 (3.6) 1.02 (0.63–1.66) 0.2 (–1.5, 1.9)
0–1 points 32/943 (3.4) Reference Reference
Recurrent VTE or clinically
relevant bleeding
3 points 121/2,010 (6.0) 1.46 (1.01–2.11) 2.0 (0.3; 3.6)
2 points 38/921 (4.1) 0.99 (0.63–1.56) 0.1 (–1.7; 1.9)
0–1 points 38/943 (4.0) Reference Reference
Abbreviations: CI, confidence interval; TTR, time in therapeutic range; VTE; venous thromboembolism.
Note: Clinical endpoints were accounted between day 31 and 180 from randomization. We calculated the SAMe-TT2-R2 score accounting for all
potentially interfering co-medications.
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anticoagulation.7,18,19 The SAMe-TT2-R2 score can classify,
among VKA-treated patients with atrial fibrillation, those in
whoman adequate TTR (e.g. more than 65% of TTR) is likely to
be achieved.11,12 In 3,874 patients randomized to the war-
farin arm of the Hokusai-VTE trial,17 we confirmed the
presence of an inverse correlation between TTR and clinical
events in VTE patients, identified independent predictors of
TTR and provided the largest validation of the SAME-TT2-R2
score. Our results suggest that a low score of less than 2
points could correctly identify patients with an ‘adequate’
TTR (above a certain threshold) only if this threshold was set
very low (e.g. 50%). Moreover, its poor discrimination (c-
statistic: 0.58), low predictive value for identifying patients
who did not do well on VKA and only marginal correlation
with clinical events suggest that the role of the SAMe-TT2-R2
score for identifying potential candidates to VKA therapy is
limited in the VTE population.
In the warfarin arm of the Hokusai-VTE trial, TTR during
stable anticoagulation after the first month from VTE diag-
nosis was good (median 66%, mean 64%). A meta-analysis of
studies from the literature calculated aweighedmean of 60%
for the same treatment period.18 In our analysis, we identi-
fied several factors influencing TTR, most of which were
already included in the SAMe-TT2-R2 score. In particular, the
Afro-American or Asian ethnicity and tobacco use proved to
be strong independent risk factors.25–27 For ethnicity, it has
been speculated that this is a consequence of genetic pre-
disposition, socio-economic status or less experience in VKA
monitoring. Furthermore, we identified a few factors sig-
nificantly associatedwith poor TTR not included in the score,
such as anaemia (which is a well-known risk factor for
bleeding after VTE20,21,28), the PE presenting location of
VTE and statin use.
The results of our analysis indicate (and confirm) that
TTR inversely correlates with recurrent thromboembolic
(ARD: þ0.5% [95% CI: 0–1.1%]) and clinically relevant bleed-
ing (ARD: þ2.2% [95% CI: 0.9–3.5%]) events occurring during
anticoagulation.6,19 In particular, it appears that TTR had a
greater impact on safety, particularly during the initial
period, when the individualized VKA dose is less likely to
be identified (►Supplementary Fig. S1, available in the
online version). These results were confirmed in a sensi-
tivity analysis focusing on the whole period of anticoagula-
tion (day 1–365). It remains to be determined whether
patients with low TTR would have had better outcomes
under DOACs.
Table 4 SAMe-TT2R2 score predicting individual TTR in warfarin-treated patients
Low SAMe-TT2-R2 score
(0–1 points)
High SAMe-TT2-R2 score
(2 points)
n (%) 943 (24.3) 2,931 (75.7)
Median TTR (IQR)a 70.7 (56.5–84.0) 64.7 (48.7–79.1)
Time above INR 3.0, median % (IQR) 10.7 (1.3–24.7) 9.5 (0.0–22.7)
Time below INR 2.0, median % (IQR) 12.4 (2.0–23.8) 18.1 (6.9–33.3)
Dependent variable: TTR < 66% (vs. TTR 66%)
OR (95% CI) Reference 1.55 (1.34–1.80)
c-Statistic (95% CI) 0.58 (0.56–0.60)
Sensitivity for TTR < 66% (95% CI)b 0.80 (0.78–0.82)
Specificity for TTR 66% (95% CI)b 0.28 (0.26–0.30)
NPV (95% CI)c 0.59 (0.56–0.62)
PPV (95% CI)c 0.52 (0.50–0.54)
Dependent variable: TTR < 50% (vs. TTR 50%)
OR (95% CI) Reference 1.86 (1.54–2.26)
c-Statistic (95% CI) 0.59 (0.57–0.61)
Sensitivity for TTR < 50% (95% CI) 0.84 (0.81–0.86)
Specificity for TTR 50% (95% CI) 0.27 (0.25–0.29)
NPV (95% CI) 0.84 (0.81–0.86)
PPV (95% CI) 0.27 (0.25–0.28)
Abbreviations: CI, confidence interval; INR, international normalized ratio; IQR, interquartile range; NPV, negative predictive value; OR, odds ratio;
PPV, positive predictive value; TTR, time in therapeutic range.
ap < 0.0001 (Wilcoxon two-sided non-parametric test).
bIndicating that 80% of patients with a TTR < 66% had a high SAMe-TT2-R2 score and that 28% of patients with a TTR 66% had a low SAMe-TT2-R2
score.
cIndicating that 59% of patients with a low SAMe-TT2-R2 score had a TTR 66% and that 52% of patients with a high SAMe-TT2-R2 score had a
TTR < 66%.
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The dichotomized SAMe-TT2-R2 score exhibited poor
NPV and PPV if the somehow standard TTR threshold of
66% was used. Moreover, the SAMe-TT2-R2 used as a
continuous score had poorer discrimination (c-statistic:
0.58) when compared with the results of the derivation
study by Apostolakis et al (0.72), irrespective of the time-
frame considered (day 31–180 or day 1–365). Indeed, the c-
statistic was similar to other external validation stu-
dies.13,15,29,30 Such differences are not surprising, since
the performance of risk prediction models in external
validation studies is usually worse than in derivation
cohorts.31 This observation confirms the results of a recent
meta-analysis of validation studies32 and contributes to
raise the question about the clinical role of the SAMe-
TT2-R2 score, especially if one considers that 76% of
patients were classified within the high SAMe-TT2-R2 class
(2 points). Moreover, since the score correlates with TTR,
but not clearly with clinical events, it remains unclear
whether its use may improve the management of patients
with VTE. We also observed that patients with a high (2
points or 3 points vs. < 2 points) SAMe-TT2-R2 score had
a higher risk of developing bleeding events, but somehow
exhibited lower recurrence rate, suggesting that the sub-
optimal TTR levels might have been due to fluctuations of
INR above the therapeutic range.
We acknowledge that our study has limitations. First, this
is a post hoc analysis: in Hokusai-VTE, the administration of
warfarin was based on randomization, and not guided by the
SAMe-TT2-R2 score: this prevents us from drawing firm
conclusions regarding the predictive value of the score and
its clinical usefulness. Only a management study can mini-
mize the confounding by indication, for example, for the
frequency of testing and VKA dose adjustment, and provide
substantial evidence regarding the accuracy of the SAMe-
TT2-R2 score. Moreover, the prevalence of some important
predictors (i.e. non-white ethnicity, amiodarone use) was
low and this could have led to an under-estimation of the
prognostic value of SAMe-TT2-R2, at least as compared with
the derivation cohort.9 Future studies should investigate
whether the threshold of the SAMe-TT2-R2 score needs to
be modified in non-white populations or in VTE patients.10
Indeed, the clinical utility of the score may be diminishing
with the increasing use of DOACs, which are often prescribed
independently from the quality of warfarin treatment
expected at each site or in the individual patient. Finally,
the assumption that patients with a poor TTR would do
better with one of the DOACs than on VKA is purely spec-
ulative, since it implies both a causal association between
TTR and clinical outcomes and a positive interaction with
DOAC treatment.
In conclusion, TTR, but not the SAMe-TT2-R2 score,
showed an inverse correlation with VTE recurrence and
clinically relevant bleeding. The SAMe-TT2-R2 score showed
unsatisfactory discrimination and predictive value for indi-
vidual TTR: therefore, its routine use after VTE may not
translate into clinical usefulness. Future adequately powered
studies must investigate whether the recalibration of the
score with other variables, such as the presenting location of
acute VTE, anaemia on admission or statin use, would
improve its predictive value.
What is known about this topic?
• Vitamin K antagonists (VKAs) are effective anticoagu-
lants, but they require strict monitoring to ensure both
efficacy and safety.
• The individual time in therapeutic range (TTR) mea-
sures the quality of VKA anticoagulation.
• TTR inversely correlates with the risk of thromboem-
bolic and bleeding events during VKA anticoagulation.
• In patients with atrial fibrillation, the dichotomized
SAMe-TT2-R2 score (2 vs. < 2 points) can predict if
adequate TTR is unlikely to be achieved, but it has not
been validated in large cohorts of patients with venous
thromboembolism (VTE).
What does this paper add?
• In patients on chronic anticoagulation after acute VTE
who were enrolled in the Hokusai-VTE trial, the indi-
vidual time in therapeutic range (TTR) correlated with
clinical outcomes.
• The SAMe-TT2-R2 score showed unsatisfactory discri-
mination and predictive value for individual TTR. More-
over, it did not correlate well with clinical outcomes.
• We identified additional clinical factors independently
associatedwith TTR andnot included in the SAMe-TT2-
R2, such as anaemia, the presenting location of VTE
and statin use.
• The routine use of the SAMe-TT2-R2 score in VTE
patients may not translate into clinical usefulness. The
present analysis may help to lead to an improved pre-
diction of adverse outcomes in VKA-treated patients.
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